Drugs / AC-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07083193 | Jan 2025 → Sep 2026 overdue | ulcerative colitis | Accro Bioscience (Suzhou) Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07083193 ↗ |
| Route | Oral | “administered orally” NCT07083193 ↗ |